AFP and neoplasm: The traditional peripheral blood biomarkers, including prostate-specific antigen PSA, carcinoembryonic antigen CEA, alpha-fetoprotein AFP, and cancer antigen CA, are only specific for one or a restricted range of tumors and cannot monitor tumor progression, including onset, treatment, metastasis, and recurrences.